NATIONAL INTERGROUP 7.8% STAKE IN SYSTEMED MAY BE SPRINGBOARD
NATIONAL INTERGROUP 7.8% STAKE IN SYSTEMED MAY BE SPRINGBOARD for a possible acquisition of the pharmacy benefit management firm by the FoxMeyer parent corporation. In an Aug. 5 13D filing with the Securities & Exchange Commission, National Intergroup says it believes that SysteMed "is presently undervalued" and that it "may determine to seek control" of SysteMed. FoxMeyer pointed out Aug. 12 that National Intergroup has numerous investments that are not geared towards acquisitions. The 13D language is intended to preserve all options, FoxMeyer said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth